【招商证券】 Rosy pipeline ahead, non-game segments improving.pdf

Pembina Pipeline Corp 2024年度报告

Reaccelerate on strong pipeline in FY23E

To further expand mRNA and ADC pipelines

境内恢复领先同行，Pipeline环比明显提升

连续获批版号，强化2023年Pipeline确定性

Clinical development of core pipeline products continues

2022H1收入+46.83%，归母净利+41.21%，批产产品加速放量，新型号Pipeline持续拓展

Moving into 3Q23E strong pipeline

EVIF Project Pipeline - August 2024

Plains All American Pipeline LP 2024年度报告